Fate Therapeutics Inc. (NASDAQ:FATE) shares shot up 3.1% on Monday . The stock traded as high as $2.77 and last traded at $2.70, with a volume of 60,680 shares trading hands. The stock had previously closed at $2.62.

FATE has been the subject of a number of research analyst reports. BMO Capital Markets set a $4.00 price objective on Fate Therapeutics and gave the stock a “buy” rating in a report on Monday, August 8th. HC Wainwright restated a “buy” rating on shares of Fate Therapeutics in a report on Tuesday, August 9th. Zacks Investment Research upgraded Fate Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a report on Thursday, August 11th. Leerink Swann restated an “outperform” rating and set a $4.00 price objective on shares of Fate Therapeutics in a report on Tuesday, June 21st. Finally, Wells Fargo & Co. restated a “buy” rating on shares of Fate Therapeutics in a report on Tuesday, May 10th. Eight investment analysts have rated the stock with a buy rating, Fate Therapeutics currently has an average rating of “Buy” and an average target price of $6.29.

The company’s market capitalization is $78.01 million. The stock’s 50 day moving average is $2.21 and its 200 day moving average is $1.91.

Fate Therapeutics (NASDAQ:FATE) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.03. The business had revenue of $1.03 million for the quarter, compared to the consensus estimate of $1.02 million. Analysts anticipate that Fate Therapeutics Inc. will post ($1.12) earnings per share for the current year.

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.